GLP-1s & Weight Loss
Mazdutide
← Back to Library
Human trial protocol Protocol not independently verified Incretin Metabolic Thermogenic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10 mg
Dosing window: Morning
Receptor / target: GLP-1; Glucagon
Properties: Incretin
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 3.0mg once weekly | Initiation dosing. |
| Weeks 5-8 | 4.5mg once weekly | Standard escalation. |
| Weeks 9-12 | 6.0mg once weekly | Advanced therapeutic phase. |
| Weeks 13+ | 9.0mg once weekly | Maximum dosage for non-responders. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: Low Start
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1.5mg once weekly | For users transitioning from other GLP-1s to assess dual-agonist tolerance. |
| Weeks 5-8 | 3.0mg once weekly | Moves to standard initiation. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2.5 mg 1x Weekly | |
| Weeks 5-8 | 5 mg 1x Weekly | |
| Weeks 9-12 | 7.5 mg 1x Weekly | |
| Weeks 13+ | 10 mg 1x Weekly |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1; Glucagon); route Subcutaneous; timing Morning. Trial exposure can explain a dose range; it does not validate every goal, stack, or long-term cycle. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Independent evidence
Clinical trial regimen(s): Phase 2: once-weekly SC mazdutide 3, 4.5, or 6 mg for 24 weeks. | GLORY-1 phase 3: once-weekly mazdutide 4 mg or 6 mg for 48 weeks in Chinese adults with overweight/obesity.
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: investigational not FDA approved
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Personal or family history of thyroid C-cell tumors.
- Active or history of acute pancreatitis.
- Pre-existing severe liver disease (cirrhosis, acute hepatic failure): despite hepatoprotective research data, severe hepatic impairment alters drug metabolism unpredictably.
- Severe gastroparesis or clinically significant delayed gastric emptying.
- Pre-existing cardiac arrhythmias or clinically significant tachycardia: glucagon receptor activation elevates heart rate.
- Type 1 diabetes mellitus.
- Diabetic ketoacidosis.
- Pregnancy: insufficient safety data; discontinue prior to planned conception.
- Breastfeeding: insufficient safety data.
- Known hypersensitivity or anaphylaxis to mazdutide or any formulation excipient.
- Concurrent use with any other GLP-1 receptor agonist, dual incretin agonist, or glucagon receptor agonist: direct pharmacological conflict.
- Severe inflammatory bowel disease or active Crohn's disease: GI motility impairment may worsen symptoms.
- Planned general anesthesia or elective surgery: delayed gastric emptying raises pulmonary aspiration risk; follow pre-operative fasting protocols.
- Concomitant use of insulin or sulfonylureas without dose adjustment: significantly elevated hypoglycemia risk.
- Concomitant use of warfarin or narrow therapeutic index oral medications: delayed gastric emptying alters absorption kinetics and may affect INR.
- End-stage renal disease: safety not established.
- Pediatric use: safety and efficacy not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Diarrhea: most frequently reported adverse event (~36% of subjects); higher rate than pure GLP-1 agonists, likely attributable to glucagon receptor contribution to GI motility.
- Decreased appetite (~29%): a pharmacological effect that directly contributes to weight loss.
- Nausea (~23%): most common during dose escalation; predominantly mild to moderate.
- Vomiting (~14%): more frequent during escalation phases; generally mild to moderate.
- Abdominal pain and cramping.
- Constipation.
- Abdominal distension and bloating.
- Dyspepsia (indigestion).
- Gastroparesis: delayed gastric emptying; clinically relevant for surgical anesthesia planning.
- Gastroesophageal reflux disease (GERD) exacerbation.
- Fatigue and lethargy: frequently secondary to caloric deficit.
- Elevated resting heart rate: mild increases of 2-4 BPM typical; occasional transient supraventricular arrhythmias observed in ECG monitoring during trials.
- Headache.
- Dizziness.
- Hypoglycemia (~10%): predominantly in subjects on concomitant insulin or sulfonylureas; low risk in non-diabetic monotherapy use.
- Acute pancreatitis: theoretical class risk; incidence was low and comparable to placebo in mazdutide trials.
- Cholelithiasis (gallstones): risk increases with rapid weight loss.
- Lean body mass reduction: some loss of lean mass accompanies fat loss; long-term implications require further study.
- Thyroid C-cell tumor risk: confirmed in rodent models; human risk not established; monitor for neck mass, hoarseness, or dysphagia.
- Injection site reactions: redness, swelling, or itching; transient and self-resolving.
- Anaphylaxis and angioedema: rare but documented across the incretin class.
- Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
- Rapid weight regain upon discontinuation: expected without sustained lifestyle intervention.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: